The safety of dopamine agonists in the treatment of Parkinson's disease

Expert Opinion on Drug Safety

Volumn 7, Issue 2, 2008, Pages 111-127

  Bonuccelli, Ubaldo ^a   Ceravolo, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adverse effects; Dopamine agonists; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CIPROFLOXACIN; CLOZAPINE; DIHYDROERGOCRYPTINE; DOMPERIDONE; DONEPEZIL; DOPAMINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOTAMINE; FENFLURAMINE; FLUVOXAMINE; LEVODOPA; LISURIDE; METHYSERGIDE; PERGOLIDE; PHENTERMINE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; PROCAINAMIDE; ROPINIROLE; ROTIGOTINE; TRIMETHOPRIM; UNINDEXED DRUG;

ADJUVANT THERAPY; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HALLUCINATION; HEART MUSCLE FIBROSIS; HUMAN; HYPERSEXUALITY; LEUKOPENIA; LUNG DISEASE; MENTAL DISEASE; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PSYCHOSIS; RETCHING; RETROPERITONEAL FIBROSIS; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; SOMNOLENCE; VALVULAR HEART DISEASE; VISUAL HALLUCINATION; VOMITING; YAWNING;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 41349093378     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.2.111     Document Type: Review

References (195)

1. Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 2004;111:1375-446
2. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003;16(Suppl 1):S13-S19.
3. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa (056 Study Group). N Engl J Med 2000;342(20):1484-91
4. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA 2000;284(15):1931-8
5. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients. The PELMOPET study. Mov Disord 2006;21(3):343-53
6. Bracco F, Battaglia A, Chouza C, et al. PKDS009 Study Group. Long-acting dopamine receptor agonist cabergoline in early Parkinson's disease, final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18(11):733-46
7. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41(4):261-309
8. Splinter MY, Pharmd. Rotigotine. transdermal dopamine agonist treatment of Prkinson's disease and restless legs syndrome. Ann Pharmacot 2007;41(2):285-95
9. Deleu D, Hanssens Y, Northway MG. Subcutaneus apomorphine an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21:687-709
10. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001;24(3):163-9
11. Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005;28(3):106-10
12. Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother 2006;6(1):81-9
13. Horstink M, Tolosa E, Bonuccelli U, et al. European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I. Early uncomplicated Parkinson's disease. Eur J Neurol 2006;13(11):1170-85
14. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment intervention for Parkinson's disease: an evidence-based assessment. Lancet 2002;359(9317):1589-98
15. Goetz GC, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatment of Parkinson's disease: 2001 to 2004, Mov Disord 2005;20(5):523-39
16. Pahwa R, Factor SA, Lyons KE, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based rewiev): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):983-95
17. Factor SA. Intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004;62(Suppl 4):12-17
18. Katzenschlager R, Hughes A, Evans A, et al. Continuous sc apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20(2):151-7
19. Morgan JC, Sethi KD. Rotigotine for the treatment of Parkinson's disease. Expert Rev Neurother 2006;6(9):1275-82
20. Jansen PA, Herings RM, Samson MM, et al. Quick titration of pergolide in cotreatment with domperidone is safe and effective. Clin Neuropharmacol 2001;24(3):177-80
21. Johns DW, Ayers CR, Carey RM. The dopamine agonist bromocriptine induces hypotension by venous and arteriolar dilation. J Cardiovasc Pharmacol 1984;6(4):582-7
22. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000;57(10):1461-3
23. Bonuccelli U, Lucetti C, Del Dotto P, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 2003;60(10):1400-4
24. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006;16(1):46-54
25. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral oedema. Arch Neurol 2000;57:729-32
26. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003;26(3):109-111
27. McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988;148:2231-6
28. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-6
29. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease, Mayo Clin Proc 2003;78:730-1
30. van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valve disease in patients with Parkinson's disease treated with high dose pergolide. Neurology 2003;61:859-61
31. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-4
32. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot-derivative dopamine agonists. Mov Disord 2004;19:656-62
33. Kim JY, Chung EJ, Park SW, Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006;21:1261-64
34. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease. A case-control study. Neurology 2006;67:1225-9
35. Zadikoff C, Rochon P, Lang. Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 2006;33:27-33
36. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease in patients treated with dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46
37. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-7
38. Dhawan V, Medcalf P, Stegie F, et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patient treated with cabergoline. J Neural Transm 2005;112:661-8
39. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002;10:334-6
40. Rascol O, Pathak A, Bagheri H, Montastruc JL. New concerns about old drugs: valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 2004;19:611-13
41. Chaudhuri KR, Dhavan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord 2004;19:1522-3
42. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation 2006;114:e84-e231
43. Connolly HM, Crary JL, Mcgoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8
44. Thorson AH. Endocardial sclerosis and other heart lesions in the carcinoid disease. Acta Med Scand Suppl 1958:99-119
45. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot-derivates alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2
46. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluraminederivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002; 144:1065-73
47. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41
48. Jahnichen S, Horwski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005;513:225-8
49. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29(2):80-6
50. Davidoff R, Mctiernan A, Constantine G, et al. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001;161:1429-36
51. Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs controls: an echocardiographic study. Mov Disord 2006;21:1109-13
52. Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonist: a rider blinding monocenter echocardiography study. Mov Disord 2007;22(2):234-8
53. Tovar EA, Landa DW, Borsari BE. Dose effect of fenfluramine phentermine in the production of valvular heart disease. Ann Thorac Surg 1999;67:1213-14
54. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-7
55. Lepor NE, Gross SB, Daley WL, et al. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000;86:107-10
56. Burger AJ, Charlamb MJ, Singh S, Notarianni M, Blackburn GL, Sherman HB. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Int J Cardiol 2001;79:159-65
57. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine-agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38
58. Olivieri RR, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induce dyskinesia in PD. Neurology 1999;53(7):1425-30
59. Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2006;21(5):654-9
60. Thomas A, Bonanni L Iorio AD, et al. End-of-dose deterioration in non-ergolinic dopamine agonist monotherapy of Parkinson's disease. J Neurol 2006;253(12):1633-9
61. Frucht SJ, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-10
62. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 2000;355:1333-4
63. Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet 2000;355:1332-3
64. Ferreira JJ, Thalamas C, Montastruc JL, Castro-Caldas A, Rascol O. Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. J Neurol 2001;248(5):426-7
65. Olanow CW, Schapira A, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord 2000;15:212-15
66. Sanjiv CC, Schulzer M, Mak E, et al. Daytime somnolence in patients with Parkinson's disease. Parkinsonism Relat Disord 2001;7:283-6
67. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson Disease. A survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-63
68. O'Suilleabhain PE, Dewey RB. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol 2002;59:986-9
69. Tan EK, Lum SY, Fook-Chong SMC, et al. Evaluation of somnolence in Parkinson's disease: comparison with age and sex-matched controls. Neurology 2002;58:465-8
70. Högl B, Seppi K, Brandauer E, et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 2003;18:319-23
71. Furumoto H. Excessive daytime somnolence in Japanese patients with Parkinson's disease. Eur J Neurol 2004;11:535-40
72. Ferreira JJ, Desboeuf K, Galitzky M, et al. Sleep disruption, daytime somnolence and "sleep attacks" in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006;13:209-14
73. Happe S, Berger K; On Behalf of the Faqt Study Investigators. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease. A prospective study. J Neurol 2001;248:1062-7
74. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Paskinson's disease. Neurology 2001;57:1392-6
75. Pal S, Bhattacharja KF, Agapito C, Chauduri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 2001;108:71-7
76. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (non-ergot) dopamine agonists. Arch Neurol 2004;61:97-102
77. Montastruc JL, Brefel-Courbon C, Senard JM, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001;3:181-3
78. Schlesinger I, Ravin PD. Dopamine agonists induce episodes of irresistible daytime sleepiness. Eur Neurol 2003;49:30-3
79. Paus S, Brecht HM, Köster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;6:659-7
80. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003;18:668-72
81. Körner Y, Meindorfner C, Möller JC, et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 2004;19:1298-305
82. Avorn J, Schneewiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005;62:1242-8
83. Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord 2001;16:500-6
84. Fabbrini G, Barbanti P, Aurilia C, Vanacore N, Paoletti C, Meco G. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov Disord 2002;17:1026-30
85. Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol 2005;12:199-207
86. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25(8):905-9
87. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18(3):287-93
88. Paus S, Seeger G, Brecht HM, et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Patkinson's disease. Mov Disord 2004;19(6):705-7
89. Risling I, Jeller F, Bandmann O, et al. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting sleep attacks. Mov Disord 2004;19(11):1279-84
90. Risling I, Korner Y, Geller F, Stiasny-Kolster K, Oertel WH, Moller JC. Preprohypocretin polymorphisms in Parkinson disease patients reporting sleep attacks. Sleep 2005;28(7):871-5
91. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol 2005;252:1223-8
92. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-8
93. Graham JM, Grünewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:434-40
94. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:533-5
95. Fenelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000;123:733-45
96. De Maindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson's Disease: a follow-up study. Mov Disord 2005;20:212-17
97. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65:115-38
98. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-8
99. Cummings JL. Behavioural complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-16
100. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. Arch Neurol 1999;56:595-601
101. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005;4:605-10
102. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease. Phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28:215-19
103. Fenelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson's disease. J Neurol 2002;249:1699-703
104. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's clisease. Parkinsonism Relat Disord 2004;10:253-4
105. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-9
106. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71
107. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol 2006;63:713-16
108. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of Levodopa therapy. Arch Neurol 1970;23:193-200
109. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993;43:S47-S52
110. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998;51:811-14
111. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-82
112. Etminan M, Gill S, Samii A. Comparison of risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis, Drug Saf 2003;26(6):439-44
113. Friedman JH. The management of the Levodopa psychoses. Clin Neuropharmacol 1991;14:283-95
114. Mendis T, Barclay CL, Mohr E. Drug-induced psychosis in Parkinson's disease. A review of management. CNS Drugs 1996;5:166-74
115. Horstink M, Tolosa E, Bonuccelli U, et al.; European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part II. Late (complicated) Parkinson's disease. Eur J Neurol 2006;13(11):1186-202
116. Shergil SS, Walker Z, LE Katona C. A preliminary investigation of laterality in Parkinson's disease and susceptibility to psychosis. J Neurol Neurosurg Psychiatry 1998;65(4):610-11
117. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous Levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998;50:515-17
118. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999;52(7 Suppl 3):S10-S13
119. Ondo WJ, Levy JK, Voung KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-5
120. Goetz C, Blasucci L, Leurgans S, Pappert E. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:748-9
121. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopaminetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-45
122. Mohr E, Mendis T, Hildebrand K, DE Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15:1230-7
123. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH, Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000;12:364-9
124. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15:301-4
125. Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994;343:1370-1
126. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998;121:1819-40
127. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006;66:93-8
128. Meco G, Bonifati V, Cusimano G, Fabrizio E, Vanacore N, Hallucinations in Parkinson disease: neuropsychological study. Ital J Neurol Sci 1990;11:373-9
129. Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord 2006;21:267-70
130. Paleacu D, Schechtman E, Inzelberg R. Association between family history of dementia and hallucinations in Parkinson disease. Neurology 2005;64:1712-15
131. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 1996;44:296-9
132. Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FM. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996;23:794-7
133. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 1990;13:296-302
134. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998;21:289-95
135. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005;20:130-40
136. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993;34:710-14
137. Pappert EJ, Goetz CG, Niederman FM, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999;14:117-21
138. Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep-wake cycle in PD: a 24-h continuous polysomnographic study. Neurology 2002;59:1979-81
139. Onofrj M, Thomas A, D'Andreamatteo G, et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci 2002;23:S91-S94
140. Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behaviour disorders in patients with Parkinson's disease. Mov Disord 2003;18:812-17
141. Kulisevsky J, Roldan E. Hallucinations and sleep disturbances in Parkinson's disease. Neurology 2004;63:S28-S30
142. Ferini-Strambi L, DI Gioia MR, Castronovo V, Oldani A, Zucconi M, Cappa SF. Neuropsychological assessment in idiopathic REM sleep behaviour disorder (RBD): does the idiopathic form of RBD really exist? Neurology 2004;62:41-5
143. Sinforiani E, Zagaglia R, Manni R, et al. REM sleep behaviour disorder, hallucinations, and cognitive impairment in Parkinson's disease. Mov Disord 2006;21:462-6
144. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease. A medical hypothesis. Neurology 2000;55:281-8
145. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727-33
146. Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000;10:43-8
147. Goetz CG, Burke PF, Leurgans S, et al. Genetic variations analysis in Parkinson disease patients with and without hallucinations. Arch Neurol 2001;58:209-13
148. Wang J, Zhao C, Chen B, Liu ZL. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease. Neurosci Lett 2004;355:193-6
149. Steckler T, Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav Brain Res 1995;67:165-99
150. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171-4
151. Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003;16:184-8
152. Ismail MS, Richard IH. A reality test: how well do we understand psychosis in Parkinson's disease? J Neuropsychiatry Clin Neurosci 2004;16(1):8-18
153. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63
154. French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999;353:2041-2
155. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59:3-7
156. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-7
157. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-6
158. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-81
159. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003;18:510-14
160. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19:29-35
161. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63
162. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2006;22:313-8
163. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002;18:258-64
164. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002;23:41-3
165. Bergmann J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:107-10
166. Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 2005;162:2184-8
167. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathological gambling in Parkinson's disease: a behavioural manifestation of pharmacologic treatment? Mov Disord 2000;15:869-72
168. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2001;61:422-3
169. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-81
170. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonist: not such a rarity. Mov Disord 2006;21:2206-8
171. Imamura A, Uitti RJ, Wszolek ZK. Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord 2006;12:506-8
172. Wintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-73
173. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathological gambling and medication association in Parkinson disease. Neurology 2006;66:1750-2
174. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006;21:2068-72
175. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviours in Parkinson disease. Neurology 2006;67:1254-7
176. Gschwandtner U, Aston J, Renaud S, Fuhr P. Pathological gambling in patients with Parkinson's disease. Clin Pharmacol 2001;24:170-2
177. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical feature associated with impulse control disorders in Parkinson disease. Neurology 2006;67:1258-61
178. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol 2006;63:298
179. Morgan JC, Iyer SS, Sethi KD. Impulse control disorders and dopaminergic drugs. Arch Neurol 2006;63:289-99
180. Menza M. The personality associated with Parkinson's disease. Curr Psychiatry Rep 2000;2:421-6
181. Voon V. Repetition, repetition and repetition: compulsive and Punding behaviours in Parkinson's disease. Mov Disord 2004;19:367-70
182. Vogel HP, Shiffer R. Hypersexuality: a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 1983;16:107-10
183. Harvey NS. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry 1988;153:833-6
184. Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989;12:375-83
185. O'Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998;13:536-39
186. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-6
187. Drapier S, Verin M. Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease. Rev Neurol 2006;162:1019-23
188. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-8
189. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson's disease. Neurology 2007;68:272-76
190. Moeller JC, Koerner Y, Dodel RC, et al. Pharmacotherapy of Parkinson disease in Germany. J Neurol 2005;252:926-35
191. Mueller T, Voss B, Hellwig K, Josef Stein F, Schulte T, Przuntek H. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. CNS Drugs 2004;18:105-11
192. Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH. Costs of drug treatment in Parkinson's disease. Mov disord 1998;13:249-54
193. Vossius C, Gjerstad M, Baas H, Larsen JP. Drug costs for patients with Parkinson's disease in two different European countries. Acta Neurol Scand 2006;113:228-32
194. Kim JS, Sohn YH. Current status of Parkinson's disease treatment in Korea. Parkinsonism Relat Disord 2003;(Suppl 2):S99-S104
195. Shimbo T, Hira K, Takemura M, Fukui T. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. Pharmacoeconomics 2001;19:875-86